VI Partners related stories
All articles and analysis
- Endosense Names Nicolas Marsault CFO
Endosense, a Geneva-based medical technology company, has named Nicolas Marsault as its new CFO. Marsault has previously worked in a variety of managerial positions at Merck Serono. He replaces Endosense’s previous chief financial officer, Andrea Buscaglia.
- Endosense Closes $40.3M Series C
Endosense, a developer of technology for catheter ablation for the treatment of cardiac arrhythmias, has raised $40.3 million in Series C financing. new investor NGN Capital led the round, which included investment from existing investors Edmond de Rothschild Investment Partners, NeoMed Management, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. Endosense was formed in Geneva in 2003.
- Delenex Therapeutics Inks $19.3M
Zurich-based Delenex Therapeutics has closed on an additional $13 million euro ($19.3 million) to bring its Series A round to 23.5 million euro ($34.8 million). Novo Ventures led the latest tranche, with participation from SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners. Delenex is a biotech company developing therapeutic antibody fragments for diseases with high unmet need.
- NovaShunt Raises $25M in Series B
Swiss medical device start-up NovaShunt AG has raised roughly $25 million in Series B financing. BioMedInvest AG, Entrepreneurs Fund and Capricorn Health-tech Fund co-led the round, which included participation from existing shareholders NeoMed and VI Partners. NovaShunt is developing an implantable pump system that continually removes excess abdominal fluid in patients suffering from liver cirrhosis, certain cancers and congestive heart failure.
- Germany’s Activaero Inks $6.8M
Activaero GmbH, a German developer of controlled breathing inhalation devices, has raised 5 million euro ($6.8 million) in venture capital financing. Amsterdam-based LSP Life Sciences Partners led the round with a 3.5 million euro investment. The firm was joined by existing shareholders including BioMedPartners, VI Partners, Abalis Finance, Vesalius Biocapital I SICAR, MedVenture Partners.
- Delenex Therapeutics Closes $14M Series A Funding Round
Delenex Therapeutics AG completed its Series A funding round at CHF 13.5 million ($14 million). SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners led the financing. Delenex is a Zurich-Schlieren, Switzerland-based biotechnology company that develops therapeutic antibody fragments.
- JenaValve Raises €19 Million
JenaValve, a German maker of aortic valves, has raised €19 million in Series B funding. Backers include GIMV, Atlas Venture, Edmond de Rothschild Investment Partners, Neomed Management, VI Partners and Sunstone Capital.
- peHUB Wire: Tuesday, March 30, 2010
Random Ramblings